On Monday, Cytek BioSciences Inc (NASDAQ: CTKB) was 5.10% up from the session before settling in for the closing price of $6.47. A 52-week range for CTKB has been $4.66 – $9.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 36.02% over the last five years. When this article was written, the company’s average yearly earnings per share was at 34.24%. With a float of $116.78 million, this company’s outstanding shares have now reached $129.77 million.
The firm has a total of 676 workers. Let’s measure their productivity. In terms of profitability, gross margin is 54.92%, operating margin of -11.75%, and the pretax margin is -5.92%.
Cytek BioSciences Inc (CTKB) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytek BioSciences Inc stocks. The insider ownership of Cytek BioSciences Inc is 9.34%, while institutional ownership is 58.03%. The most recent insider transaction that took place on Apr 19 ’24, was worth 117,400. In this transaction CHIEF TECHNOLOGY OFFICER of this company sold 20,000 shares at a rate of $5.87, taking the stock ownership to the 5,988,502 shares. Before that another transaction happened on Apr 09 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 1,900 for $7.00, making the entire transaction worth $13,304. This insider now owns 6,008,502 shares in total.
Cytek BioSciences Inc (CTKB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.24% per share during the next fiscal year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
You can see what Cytek BioSciences Inc (CTKB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.35. Likewise, its price to free cash flow for the trailing twelve months is 30.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit 0.11 in the next quarter and is forecasted to reach 0.21 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
Analysing the last 5-days average volume posted by the [Cytek BioSciences Inc, CTKB], we can find that recorded value of 0.58 million was lower than the volume posted last year of 0.69 million. As of the previous 9 days, the stock’s Stochastic %D was 49.34%. Additionally, its Average True Range was 0.36.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 72.05%, which indicates a significant decrease from 89.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.43% in the past 14 days, which was lower than the 75.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.80, while its 200-day Moving Average is $6.00. Now, the first resistance to watch is $6.96. This is followed by the second major resistance level at $7.13. The third major resistance level sits at $7.37. If the price goes on to break the first support level at $6.55, it is likely to go to the next support level at $6.31. Now, if the price goes above the second support level, the third support stands at $6.14.
Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats
There are 128,811K outstanding shares of the company, which has a market capitalization of 875.91 million. As of now, sales total 193,020 K while income totals -12,150 K. Its latest quarter income was 51,500 K while its last quarter net income were 940 K.
